Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIN + sintilimab
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
PIN + sintilimab is an investigational combination therapy consisting of a Pyroptosis-inducible Newcastle Disease Oncolytic Virus (PIN) and the PD-1 checkpoint inhibitor sintilimab. PIN is an oncolytic virus engineered to selectively infect and replicate within tumor cells, triggering pyroptosis—a highly inflammatory form of programmed cell death. This process releases tumor-associated antigens and pro-inflammatory cytokines, effectively converting the tumor microenvironment from "cold" to "immunologically hot." Sintilimab is a humanized monoclonal antibody that blocks the interaction between the Programmed Cell Death Protein 1 (PD-1) receptor on T cells and its ligands (PD-L1/PD-L2), thereby preventing immune evasion. The combination is specifically being evaluated by the Chinese PLA General Hospital for the treatment of advanced proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer with hepatic metastases, a population that typically shows poor response to single-agent checkpoint inhibition.
- Brand names
- Tyvyt
- Other names
- Pyroptosis-inducible Newcastle Disease Oncolytic Virus + sintilimabPIN plus sintilimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PIN + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIN + sintilimab.